Landscapes / Companies
Beijing InnoCare Pharma Tech Co., Ltd. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
2 approved
3 in Phase 3
Drugs
17
in active trials · 22 in all
Trials
29 active
60 since 2021
Drugs17
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Bruton's tyrosine kinase inhibitor |
Approved in China | 31 Aug 2028Phase 3 trial completes | |||
| How it works | Blocks BTK | ||||
| Next date | 31 Aug 2028 · Phase 3 trial completes | ||||
| Also tested for | Part 1:r/r B-cell Malignancies, Part 2:B-cell Malignancies and 7 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved in China | Sep 2028Phase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | Sep 2028 · Phase 3 trial completes | ||||
| Also tested for | DLBCL | ||||
| Open drug page | |||||
— |
Phase 3 | 25 Nov 2026soonPhase 3 trial completes | |||
| Next date | 25 Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | Atopic Dermatitis, Non Segmental Vitiligo and 1 more | ||||
| Open drug page | |||||
— |
Phase 3 | Mar 2027Phase 2 trial completes | |||
| Next date | Mar 2027 · Phase 2 trial completes | ||||
| Also tested for | Plaque Psoriasis Patients, Cutaneous Lupus Erythematosus (CLE) and 1 more | ||||
| Open drug page | |||||
Mesutoclaxnot checked |
— |
Phase 3 | Dec 2027Phase 2 trial completes | ||
| Next date | Dec 2027 · Phase 2 trial completes | ||||
| Also tested for | Relapsed or Refractory Mantle Cell Lymphoma (MCL), Hematological Malignancies and 6 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 28 Dec 2026Phase 1/2 trial completes | |||
| Next date | 28 Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Hematoma | ||||
| Open drug page | |||||
— |
Phase 2 | Mar 2027Phase 2 trial completes | |||
| Next date | Mar 2027 · Phase 2 trial completes | ||||
| Also tested for | Prurigo Nodularis (PN) | ||||
| Open drug page | |||||
— |
Phase 1/2 | Sep 2027Phase 1/2 trial completes | |||
| Next date | Sep 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumor | ||||
| Open drug page | |||||
— |
Phase 1/2 | 25 Dec 2027Phase 1/2 trial completes | |||
| Next date | 25 Dec 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Solid Tumors, Advanced Solid Tumors Harboring NTRK Fusion and 1 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | Jul 2028Phase 1/2 trial completes | |||
| Next date | Jul 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Relapsed or Refractory Non-Hodgkin Lymphoma | ||||
| Open drug page | |||||
— |
Phase 1/2 | Dec 2030Phase 1/2 trial completes | |||
| Next date | Dec 2030 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumor | ||||
| Open drug page | |||||
— |
Phase 2 | — | |||
| Also tested for | Intrahepatic Cholangiocarcinoma (ICC) | ||||
| Open drug page | |||||
— |
Phase 1 | Mar 2028Phase 1 trial completes | |||
| Next date | Mar 2028 · Phase 1 trial completes | ||||
| Also tested for | Inflammatory Bowel Disease(IBD) | ||||
| Open drug page | |||||
— |
Phase 1 | Jun 2029Phase 1 trial completes | |||
| Next date | Jun 2029 · Phase 1 trial completes | ||||
| Also tested for | Advanced Solid Tumors | ||||
| Open drug page | |||||
— |
Phase 1 | — | |||
| Also tested for | Advanced Solid Tumors and Hematologic Malignancies | ||||
| Open drug page | |||||
ICP-248 + Orelabrutinibnot checked |
— |
Phase 1 | — | ||
| Also tested for | Hematological Malignancies | ||||
| Open drug page | |||||
— |
Phase 1 | — | |||
| Also tested for | Health Services Research | ||||
| Open drug page | |||||
No drugs match “”.
About
- No active trial
- ICP-033, ICP-105, ICP-189, Orelabrutinib and R-CHOP, Recombinant humanized monoclonal antibody MIL62
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021